lystn

In this CCO Nephrology podcast episode, hear from nephrologists Pietro Canetta, MD, MS, and Andy Bomback, MD, PhD, experts in clinical management and research on glomerular diseases as they discuss key updates in managing IgAN. Faculty highlight the importance of a comprehensive supportive care regimen to protect patients’ kidneys and prevent progression of disease. In addition, they review the merits and place in therapy of novel and emerging therapies. 

 Topics include:

• Supportive care as the foundation of IgAN management
• Place in therapy for new and emerging agents
  • Targeted-release formulation of budesonide
  • Endothelin receptor antagonists (eg, sparsentan)
  • Factor B inhibitors (eg, iptacopan)
• The role of clinical trial involvement

Learn more about IgA nephropathy with educational activities and resources here:  

• CME-certified text module with animated pathophysiology video and patient voice audio clip
• ClinicalThought commentaries
• Resources on IgAN from the American Kidney Fund